Esther Bouman‐Thio

Author

Esther Bouman‐Thio

Janssen (United States)

Also Known As

E BOUMANTHIO, Esther Bouman-Thio, Esther Bouman‐Thio

Publications

822

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Clinical and Laboratory Standards Institute Janssen (Belgium)Springhouse Centre for Human Drug Research

About

Esther Bouman‐Thio is an author at Janssen (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	645
2	Pharmacology	7	7	404
3	Immunology	5	5	536
4	Rheumatology	2	2	202
5	Epidemiology	1	1	32

Esther Bouman‐Thio

Publications

822

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis Honghui Zhou, Haishan Jang, Roy Fleischmann, The Journal of Clinical Pharmacology InflammationRheumatologyRheumatoid DisorderAutoimmune DiseasePharmacokinetic Modeling	2007	191
Monoclonal antibody-induced cytokine-release syndrome Peter J. Bugelski, Ram Achuthanandam, Renold J. Capocasale, Expert Review of Clinical Immunology InflammationCytokineAutoimmune DiseaseFew MabsImmunology	2009	159
Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study Zhenhua Xu, Esther Bouman‐Thio, Craig Comisar, British Journal of Clinical Pharmacology	2011	96
Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects Zhenhua Xu, Qingmin Wang, Yanli Zhuang, The Journal of Clinical Pharmacology Healthy SubjectsSc GolimumabSubcutaneous BioavailabilityHematologyImmunology	2009	93
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis Yanli Zhuang, César A. Calderón, Stanley J. Marciniak, European Journal of Clinical Pharmacology Autoimmune DiseaseHealthy SubjectsMedicineImmunologyClinical Dermatology	2016	82
A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects Esther Bouman‐Thio, Kari L. Franson, Bruce Miller, The Journal of Clinical Pharmacology	2008	41
Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects Juan José Pérez Ruixo, Wojciech Krzyżański, Esther Bouman‐Thio, Clinical Pharmacokinetics Pharmacokinetic ModelingHealthy SubjectsMedicineHematologyClinical Pharmacology	2009	40
Lack of Racial Differences in the Pharmacokinetics of Subcutaneous Golimumab in Healthy Japanese and Caucasian Male Subjects Jie Ling, Sally Lyn, Zhenhua Xu, The Journal of Clinical Pharmacology Drug SafetyTranslational MedicineSubcutaneous GolimumabCaucasian Male SubjectsPharmacology	2010	32
A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. René Westhovens, Frédéric Houssiau, Johan Joly, Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))	2006	22
Comparison of the Pharmacokinetics of Subcutaneous Ustekinumab between Chinese and Non-Chinese Healthy Male Subjects across Two Phase 1 Studies Yaowei Zhu, Qingmin Wang, Bart Frederick, Clinical Drug Investigation MedicineSubcutaneous UstekinumabPharmacotherapyDermatologyScleroderma	2013	19

Page 1